^
    20h
    NCI-2014-00639: Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • etoposide IV
    23h
    A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    CD5 (CD5 Molecule)
    |
    fludarabine IV
    5d
    Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. (PubMed, Blood Cancer J)
    Three cases (8%) of non-fatal sinusoidal obstructive syndrome (SOS) were observed. Inotuzumab was safe and effective at eradicating MRD.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Besponsa (inotuzumab ozogamicin)
    5d
    PXDN, TCF4 and TSPAN7 Are Differentially Expressed in B-Cell Acute Lymphoblastic Leukaemia: An Integrative Analysis. (PubMed, Genes (Basel))
    Collectively, our results identify, for the first time, PXDN, TCF4 and TSPAN7 as differentially expressed genes in ALL and highlight the usefulness of integrative transcriptomic analyses across independent datasets. While limited by small-scale experimental validation and reliance on computational predictions, this study provides a framework for prioritising candidate genes and generates testable hypotheses regarding their potential involvement in leukaemia-associated molecular pathways.
    Journal
    |
    TCF4 (Transcription Factor 4)
    5d
    CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL. (PubMed, Int J Mol Sci)
    Clinically, elevated expression of CD40LG, CD28, RHOA, or RAC2 correlates with poor prognosis in non-ETP T-ALL patients. These findings uncover a novel CD40LG/CD28-Rho GTPase axis as a key driver of pathogenesis and a potential therapeutic vulnerability in non-ETP T-ALL, providing a new target for precision intervention and a promising strategy to overcome therapeutic resistance.
    Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD28 (CD28 Molecule) • RAC1 (Rac Family Small GTPase 1) • RHOA (Ras homolog family member A) • CD40LG (CD40 ligand) • RAC2 (Rac Family Small GTPase 2)
    5d
    Single-Cell Transcriptomic Profiling Reveals Dual Antitumor and Adaptive Resistance Mechanisms of a Novel HSP90 Inhibitor, SP11, in T-Cell Acute Lymphoblastic Leukemic Cells and DLA Mouse Model. (PubMed, Int J Mol Sci)
    Collectively, our results show that SP11 may exert both tumor-intrinsic and immune-modulating effects and reveal transcriptionally defined adaptive cellular states linked to resistance. This study provides mechanistic in sights into responses to HSP90 inhibition and supports combination approaches for improving therapeutic outcomes in T-ALL.
    Preclinical • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD44 (CD44 Molecule)
    9d
    NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL (clinicaltrials.gov)
    P1, N=10, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD38 (CD38 Molecule) • CD47 (CD47 Molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule)
    9d
    Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2030 | Trial primary completion date: Jul 2021 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD7 (CD7 Molecule)
    10d
    Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference. (PubMed, Blood Neoplasia)
    Importantly, the combination of anti-CD38 IgA2 and CD47 blockade was effective against xenografted B-ALL in human FcαRI (CD89) transgenic NXG mice. Together, these studies support combining anti-CD38 IgA2 with CD47 interference to improve myeloid effector cell recruitment for B-ALL immunotherapy.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    15d
    Tumor Treating Fields modulate apoptotic and immune programs in T-cell acute lymphoblastic leukemia cell lines. (PubMed, Exp Ther Med)
    Intracellular ATP levels were reduced in Jurkat cells, whereas no significant change was observed in MOLT-4 cells. In parallel, transcriptional analyses revealed downregulation of CD69 and IL-2 and upregulation of RELA proto-oncogene, NF-κB subunit and CBL proto-oncogene B. Collectively, these results demonstrate that TTFields induces cytostatic and apoptotic effects accompanied by measurable structural, bioenergetic and transcriptional alterations in T-ALL cells, supporting further investigation of TTFields as a physical therapeutic approach for hematologic malignancies.
    Preclinical • Journal
    |
    CD69 (CD69 Molecule) • IL2 (Interleukin 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • RELA (RELA Proto-Oncogene)
    15d
    Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)